IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
IDEAYA announced updated Phase 1 results for IDE849 (SHR-4849), its DLL3 TOP1 ADC, showing a 72.5% ORR and 17.4-month median overall survival in second-line relapsed SCLC, with the data presented by partner Hengrui at ESMO 2026. Efficacy extended to other neuroendocrine carcinomas (52.6% ORR, 7.0-month median PFS) and to SCLC patients with brain metastases (76.9% ORR), with a 2.5% treatment-related discontinuation rate across 122 patients.
Key figures
- Drug Name
- IDE849 (SHR-4849)
- Phase Of Trial
- Phase 1
- Orr nec
- 52.6%
- Orr 2l sclc
- 72.5%
- Corr 2l sclc
- 60.8%
- Grade3plus ild
- 0.8%
- Patients enrolled
- 122
- Orr all lines sclc
- 68.3%
- Orr brain metastases
- 76.9%
- Median pfs nec months
- 7
- Grade3plus trae 2.4mgkg
- 33.3%
- Median os 2l sclc months
- 17.4
- Median pfs 2l sclc months
- 6.9
- Median os 2l plus 3l sclc months
- 14.7
- Treatment related discontinuation
- 2.5%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.